Thursday, May 19, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home Latest News

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

February 18, 2022
in Latest News
0
Share on FacebookShare on Twitter

BOSTON – Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team led by investigators at Massachusetts General Hospital (MGH), is published in the New England Journal of Medicine. 

 

Standard treatment for patients with metastatic, hormone-sensitive prostate cancer includes the addition of either the chemotherapy drug docetaxel or an androgen-receptor pathway inhibitor to androgen-deprivation therapy, with the latter two treatments acting to lower the effects of androgen hormones, such as testosterone. Clinical trials that have combined all three treatments have generated conflicting results. To provide clarity, investigators designed the large, international ARASENS Trial and randomly assigned 1,306 patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive the oral androgen-receptor inhibitor darolutamide or placebo, both in combination with androgen-deprivation therapy and docetaxel. 

 

Survival rates in the two groups were compared after 533 patients had died. Patients were followed for a median of approximately 3.5 years, and those who received darolutamide had a 32.5% lower risk of dying during that time than patients not taking darolutamide. Patients taking darolutamide also experienced greater delays in developing castration-resistant prostate cancer (which no longer responds to treatments that lower testosterone), pain, and the need for other anti-cancer therapies. The combination of three medications did not result in more toxic effects compared with the combination of androgen-deprivation therapy and docetaxel alone.

 

“Despite progress in recent years, survival is short for patients with metastatic prostate cancer. Results from ARASENS are an important step forward, and triplet therapy with darolutamide should become a new standard of care for the treatment of patients with metastatic hormone-sensitive prostate cancer,” says lead author Matthew R. Smith, MD, PhD, director of the Genitourinary Oncology Program at the Mass General Cancer Center and an associate professor of medicine at Harvard Medical School.

 

Study co-authors include Maha Hussain, MD, Fred Saad, MD, Karim Fizazi, MD, PhD, Cora N. Sternberg, MD, E. David Crawford, MD, Evgeny Kopyltsov, MD, Chandler H. Park, MD, Boris Alekseev, MD, Álvaro Montesa‑Pino, MD, Dingwei Ye, MD, Francis Parnis, MB, BS, Felipe Cruz, MD, Teuvo L.J. Tammela, MD, PhD, Hiroyoshi Suzuki, MD, PhD, Tapio Utriainen, MD, Cheng Fu, MD, Motohide Uemura, MD, PhD, María J. Méndez‑Vidal, MD, Benjamin L. Maughan, MD, PharMD, Heikki Joensuu, MD, Silke Thiele, MD, Rui Li, M.S., Iris Kuss, MD, and Bertrand Tombal, MD, PhD.

 

The study was supported by Bayer and Orion Pharma.

 

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of “America’s Best Hospitals.”



Journal

New England Journal of Medicine

DOI

10.1056/NEJMoa2119115

Article Title

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Tags: cancercombinationhormonesensitivemenmetastaticprolongsprostatesurvivalThreedrug
Share28Tweet17Share5ShareSendShare
  • Gladstone scientists Tongcui Ma, Irene Chen, and Rahul Suryawanshi.

    “Natural immunity” from omicron is weak and limited, study finds

    68 shares
    Share 27 Tweet 17
  • Ecological functions of streams and rivers severely affected globally

    71 shares
    Share 28 Tweet 18
  • Scripps Research awarded $67 million by NIH to lead new Pandemic Preparedness Center

    66 shares
    Share 26 Tweet 17
  • Researchers discover genetic cause of megaesophagus in dogs

    1021 shares
    Share 408 Tweet 255
  • Do early therapies help very young children with or at high likelihood for autism?

    66 shares
    Share 26 Tweet 17
  • United States’ ocean conservation efforts have major gaps, Oregon State University analysis shows

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Understanding how sunscreens damage coral

New Curtin research resurrects ‘lost’ coral species

SUTD develops design-based activity to enhance students’ understanding in electrochemistry

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 187 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....